

Βιβλιογραφικές αναφορές: Σκλήρυνση κατά πλάκας

1. Multiple sclerosis. Mayo Clinic. Accessed Jan 2021.
2. Multiple Sclerosis. Author: Christopher Luzzio. Emedicine Medscape.
Updated: Sep 02, 2020.
3. Multiple Sclerosis: Why Are Women More at Risk? Accessed Jan. 2021. Johns Hopkins Medicine
4. Multiple sclerosis Prof Alan J Thompson et al. THE LANCET. March 2018.
5. The Mechanism of Action of Interferon- β in Relapsing Multiple Sclerosis. Bernd C. Kieseier. CNS Drugs, Springer. August 2012 volume.
6. Mitoxantrone (Rx) Medscape.
7. For RMS patients on Aubagio, elimination can be accelerated. Sanofi Genzyme, 2019.
8. Drug Approval Package: ZEPOSIA U.S. Food & Drug Administration. March 2020.
9. Impact of Exercise on Immunometabolism in Multiple Sclerosis Remsha Afzal et al. J Clin Med . 2020 Sep.
10. O'Neill, L.A.; Kishon, R.J.; Rathmell, J. A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 2016
11. Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis. Giacomo Lazzarino et al. Mol Neurobiol Springer. 2017 Nov.
12. A blood-based metabolomics test to distinguish relapsing–remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application. Tianrong Yeo et al. Nature, Scientific Reports. 24 July 2020
13. Metabolomic signatures associated with disease severity in multiple sclerosis Pablo Villoslada et al. Neurol Neuroimmunol Neuroinflamm. 2017

14. Disability in patients with multiple sclerosis: Influence of insulin resistance, adiposity, and oxidative stress. Sayonara Rangel Oliveira et al. Nutrition, March 2014.
15. Metabolic pressure and the breach of immunological self-tolerance. Veronica De Rosa, Antonio La Cava & Giuseppe Matarese. Nature Immunology. October 2017.
16. Prediction of Autoimmune Diseases by Targeted Metabolomic Assay of Urinary Organic Acids by Dimitris Tsoukalas, Vassileios Fragoulakis, Aristidis Tsatsakis, Daniela Calina et al. Metabolites Dec 2020
17. Metabolomic profile of insulin resistance in patients with multiple sclerosis is associated to the severity of the disease Alejandro Ruiz-Argüelles et al. Mult Scler Relat Disord . 2018
18. Metabolic defects in multiple sclerosis. Reginald C Adiele, Chiedukam A Adiele. Mitochondrion. 2019.
19. Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation. Bhargava P, Fitzgerald KC, Calabresi PA, Mowry EM. Journal of Clinical Investigation Insight. 2017
20. Metabolomics in multiple sclerosis disease course and progression. Pavan Bhargava, Daniel C. Anthony. Multiple Sclerosis Journal. January 22, 2020.
21. Metabolism as a Target for Modulation in Autoimmune Diseases. Nick Huang Andras Perl. Cell, Trends in Immunology May 05, 2018
22. Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. Sotirchos ES, Bhargava P. et al. Neurology. 2016 Jan.
23. Micronutrient deficiencies in patients with COVID-19: how metabolomics can contribute to their prevention and replenishment. Dimitris Tsoukalas and Evangelia Sarandi. BMJ Nutri Prev Heal. Nov. 2020;
24. Vitamin D and Multiple Sclerosis: A Comprehensive Review Martina B. Sintzel, Mark Rametta, and Anthony T. Reder. Neurol Ther Springer. 2018 Jun.
25. Vitamin D and MS: Is there any connection? Mayo Clinic Accessed Jan 2021.

26. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models Egle Cekanaviciute et al. Proc Natl Acad Sci U S A. 2017
27. Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis Qianquan Ma et al. Journal of Neuroinflammation, March 2019
28. The Central Nervous System and the Gut Microbiome Gil Sharon et al. Cell. Nov. 2016.
29. Immunomodulatory and anti-inflammatory effects of probiotics in multiple sclerosis: a systematic review Mohammad Morshedi et al. Journal of Neuroinflammation November 2019.
30. Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course R. E. Ventura et al. Nature Scientific Reports. November 2019.
31. Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know Marina Kleopatra Boziki et al. Brain Sci. 2020 Apr.
32. Nutritional factors and aging in demyelinating diseases Ana M. Adamo Genes & Nutrition. Springer 2014.
33. Analysis of the intricate effects of polyunsaturated fatty acids and polyphenols on inflammatory pathways in health and disease. Denisa Margină, Dimitris Tsoukalas, Aristides Tsatsakis et al. Food Chem Toxicol. 2020 Sep.
34. Effect of omega-3 fatty acids and fish oil supplementation on multiple sclerosis: a systematic review. Welayah Ali AlAmmar et al. Nutr Neurosci . 2019 Aug.
35. Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors. Margină, D.; Ungurianu, A.; Purdel, C.; Tsoukalas, D.; Sarandi, E.; Thanasoula, M.; Tekos, F.; Mesnage, R.; Kouretas, D.; Tsatsakis, A. Int. J. Environ. Res. Public Health 2020, 17, 4135.
36. World aging population, chronic diseases and impact of modifiable-metabolic risk factors. Dr. Dimitris Tsoukalas, MD (Greece). 20th International Congress of Rural Medicine 2018. Tokyo - Japan.